Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIAN-TU-002 platform trial of remternetug for prevention of dominantly inherited Alzheimer's disease progression
2024-517187-36-01Phase 3Authorised
- Sponsor
- Washington University School of Medicine
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Remternetug with Placebo to match LY3372993 (2 arms). Planned start Jun 2026; status: authorised.
02
Drugs
remternetug
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2024-517187-36-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517187-36-01.